| Element List | Explanation |
|---|---|
| Introduction | Middle East Pharmaceutical Industries Company announces the Board of Directors’ recommendation to the Extraordinary General Assembly to increase the company’s capital by granting shares. |
| Date of Board Meeting | 2026-01-29 Corresponding to 1447-08-10 |
| Capital before increase | SAR 200,000,000 |
| Capital after increase | SAR 350,000,000 |
| Percentage of Capital increase | 75 % |
| Number of shares before Capital increase | 20000000 |
| Number of shares after Capital increase | 35000000 |
| Reasons for the increase | To support the Company’s growth strategy, enhance its capital base, and strengthen its financial position to implement its future plans and activities, thereby contributing to enabling the Company to expand and maximize returns on shareholders’ equity. |
| Number of Shares Granted per Exiting Share | Three (3) shares for every four (4) shares held. |
| Nature and Value of Reserves Used in the Capitalization | The increase will be through capitalizing 150,000,000 SAR from the retained earnings. |
| Eligibility Date | The eligibility of the bonus shares shall be for shareholders owning shares by the end of trading day of the Company’s Extraordinary General Assembly meeting date (which will be announced later) and are registered at Securities Depository Center Company (Edaa) by the end of the second trading day following the Extraordinary General Assembly meeting date |
| Fractional Shares | In the event of fractional shares, the fractions will be collected in one portfolio for all shareholders and sold at the market price, then their value will be distributed to the shareholders entitled to the grant, each according to their share, within a period not exceeding 30 days from the date of determining the new shares due to each shareholder. |
| Approvals | The capital increase, issuance of bonus shares, and treasury shares are subject to obtaining the necessary approvals from the relevant regulatory authorities and the Company’s Extraordinary General Assembly. |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.